Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J, Wang K, Liu Y, Wang H, Fu P, Zhang S, Liu Q, Wang S, Huang J, Wang C, Wang S, Wang Y, Zhen L, Zhu X, Wu F, Lin X, Zou J.
Wu J, et al. Among authors: lin x.
BMC Med. 2022 Dec 27;20(1):498. doi: 10.1186/s12916-022-02708-3.
BMC Med. 2022.
PMID: 36575513
Free PMC article.
Clinical Trial.